With solid top-line phase IIb data for its oral insulin in hand, "everything is focused on taking this from where we are right now into a phase III trial," Chief Operating Officer Josh Hexter told BioWorld Today, adding that the company is still putting the results together and will schedule an end-of-phase-II meeting with the FDA when the package is ready.